Hypotensive effect of α-human atrial natriuretic polypeptide (α-hANP) in some experimental animals. A perspective as an antihypertensive drug

• Published in: Japanese Journal of Pharmacology Vol. 46; no. suppl; p. 41
• Main Author: Takafumi Ishihara
• Format: Journal Article
• Language: Japanese
• Published: The Japanese Pharmacological Society 1988
• ISSN: 0021-5198

We have studied the hypotensive effect of an intravenous (i.v.) administration of α-hANP in the experimental animals. In anesthetized SD rats and dogs with or without volume expansion with physiological saline solution, α-hANP lowered blood pressure and increased urine flow and urinary excretion of electrolytes. In anesthetized dogs, α-hANP selectively increased renal blood flow, but did not produce appreciable changes in blood flow in other vascular beds measured, and attenuated more markedly norepinephirine-induced hypertention than bilateral carotid artery occlusion-induced one. The repeated bolus i.v. injections within less than 60 min or the continuous infusion of α-hANP to anesthetized SD rats resulted in longer-lasting hypotention and initial short-lived diuresis. In conscious Wistar Kyoto (WKY) rats and two hypertention model rats, α-hANP lowered blood pressure most markedly in DOKA/Na hypertensive rats and then SHR and least of all in WKY rats. In isolated canine arterial and venous strips, α-hANP slightly relaxed the constrictions produced by many constrictors, and the renovascular selectivity seen in anesthetized dogs was clearly observed when high K^+ was used as a constrictor. These results indicate that α-hANP has an antihypertensive property due to systemic vasodilation.